Home

Jon Faiz Kayyem

CIK 1366268 · SVP, Research & Development · last filed 2026-09-23

Jon Faiz Kayyem is a SVP, Research & Development who has filed 104 SEC Form 4 insider transactions across 4 companies since 2010. The most recent filing shows the insider bought $500.0K of INBX on Sep 23, 2026. Across all open-market trades the lifetime net is +$2.3M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $43.8M across reported positions. 21 SEC filings were submitted jointly with Efficacy Biotech Master Fund Ltd.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$43.79M

Companies

4

Total Filings

104

Lifetime Open-Market Net

$2.30M

Filer Profile

Reported Address
5964 LA PLACE COURT
CARLSBAD, CA 92008
Related Filers
Efficacy Biotech Master Fund Ltd. — 21 joint filings, latest 2008-11-04
Efficacy Capital, Ltd. — 21 joint filings, latest 2008-11-04
Mark Lappe — 21 joint filings, latest 2008-11-04
Efficacy Biotech Fund LTD — 20 joint filings, latest 2008-11-04
Inhibrx, Inc. — 14 joint filings, latest 2024-05-30
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
INBX Director 434,360 $99.61 $43.27M $3.02M 22 2026-09-23
BDSX Director 17,877 $29.10 $520.2K $200.0K 13 2026-01-06
Inhibrx, Inc. (INBXV) Delisted Director 0 — — $0 1 2024-05-30
GenMark Diagnostics, Inc. (GNMK) Delisted SVP, Research & Development 286,306 $24.04 $6.88M -$924.2K 62 2018-02-06

Recent Filings

104 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-09-23 INBX Buy (P) +5,000 $500.0K EDGAR
2026-09-18 INBX Grant (A) — $0 EDGAR
2026-09-17 INBX Buy (P) +5,000 $500.0K EDGAR
2026-09-08 INBX Buy (P) +5,000 $567.6K EDGAR
2026-06-04 INBX Grant (A) — $0 EDGAR
2026-01-06 BDSX Grant (A) — $0 EDGAR
2025-05-29 INBX Grant (A) — $0 EDGAR
2025-05-22 BDSX Grant (A) — $0 EDGAR
2025-03-28 INBX Gift (G) −90,000 $0 EDGAR
2024-12-17 INBX Gift (G) — $0 EDGAR
Showing 1–10 of 104
Page 1 of 11
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.